Clinical efficacy of azithromycin combined simvastatin in the treatment of chronic obstructive pulmonary disease combined with pulmonary hypertension
10.13699/j.cnki.1001-6821.2015.04.003
- VernacularTitle:阿奇霉素联合辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压的临床疗效
- Author:
Xiao-Long MA
1
Author Information
1. 嘉兴市第一医院 呼吸科
- Keywords:
azithromycin;
simvastatin;
chronic obstructive pulmonary disease;
pulmonary hypertension
- From:
The Chinese Journal of Clinical Pharmacology
2015;(4):250-252,258
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of azithromycin combined simvastatin in patients with chronic obstructive pulmonary disease ( COPD ) combined with pulmonary hypertension.Methods Sixty patients with COPD combined with pulmonary hypertension were randomly divided into treatment group ( n =30 ) and control group (n=30).Patients in control group was treated with simvastatin 20 mg, based on which patients in treatment group was given azithromycin enteric-coated tablets 0.25 g.The treatment lasted for six months.Data of par-tial pressure of blood oxygen, oxygen saturation, 6 min walking distance, forced vital capacity ( FVC ) , forced expiratory volume in one second ( FEV1 ) , pulmonary systolic pressure as well as diastolic pressure and C-reactive protein ( CRP ) levels were compared between two groups before and after treatment.Results After treatment, data of partial pressure of blood oxygen, oxygen saturation, 6 min walking distance, FVC and FEV1 were significantly higher in treatment group than those before treatment ( P <0.05 ); data of f pulmonary systolic pressure, diastolic pulmonary, and CRP levels were significantly lower than those before treatment ( P <0.05 ); data of triglyceride ( TG ) , serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) was significantly lower in the treatment group than those in the control group, while high -density lipoprotein cholesterol ( HDL -C ) was significantly higher in the treatment group ( P<0.05).There was no statistically significant difference found between two groups in terms of liver function ( P>0.05 ) .Conclusion Azithromycin combined with simvastatin in the treatment of COPD with pulmonary hypertension is safe with a significant efficacy.
